We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

More sweet than sour

17 June 2005 By Robert Cyran

The French pharma s defeat in its Lovenox patent trial may seem like a critical hit it puts more than E1bn of sales at risk. But there is no way the plaintiffs can introduce a generic version of the drug.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)